Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Akshay Vaishnaw unloaded 33,480 shares of Alnylam Pharmaceuticals stock on the open market in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $60.72, for a total transaction of $2,032,905.60. Following the completion of the sale, the executive vice president now directly owns 12,588 shares of the company’s stock, valued at approximately $764,343. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $82.00 in a research note to investors on Monday, November 11th. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Friday, November 8th. They now have a $53.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Wednesday, October 9th. They now have a $60.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $62.25.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 0.35% during mid-day trading on Thursday, hitting $62.78. 168,168 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 52 week low of $17.31 and a 52 week high of $66.17. The stock has a 50-day moving average of $57.83 and a 200-day moving average of $50.62. The company’s market cap is $3.982 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 46.4% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.38 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.